Thrombosis research
-
Thrombosis research · Mar 2010
Randomized Controlled Trial Multicenter StudyBolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism.
The clinical benefit of thrombolytic treatment over heparin in patients with pulmonary embolism without hemodynamic compromise remains controversial. In these patients bolus tenecteplase has the potential to provide an effective and safe thrombolysis. ⋯ In hemodynamically stable patients with PE, treatment with single bolus tenecteplase is feasible at the same dosages used for acute myocardial infarction and is associated with reduction of RVD at 24 hours. Whether this benefit is associated with an improved clinical outcome without excessive bleeding is currently explored in a large clinical trial.